Nxera Pharma Co Ltd (4565)

Currency in JPY
868.0
-8.0(-0.91%)
Closed·

Nxera Pharma (4565) Earnings Dates & Reports

Latest Release
Feb 13, 2026
EPS / Forecast
-- / -20.06
Revenue / Forecast
-- / 14.31B
EPS Revisions
Last 90 days
Release Date
Period End
EPS
/Forecast
Revenue
/Forecast
EPS Surprise %
Revenue Surprise %
Reaction
03/2026--/----/------Free Sign Up
12/2025--/-20.06--/14.31B----Free Sign Up
09/2025-18.49/22.296.75B/7.75B-182.95%-12.9%Free Sign Up
06/2025-26.37/17.838.45B/10.15B-247.9%-16.75%Free Sign Up
03/2025-8.45/--6.64B/7.15B---7.13%Free Sign Up
12/2024-14.86/60.26.85B/13.73B-124.68%-50.11%Free Sign Up
09/202413.45/0.2829.26B/12.56B+4,676.28%-26.27%Free Sign Up
06/2024-15.83/0.088.11B/8.53B-19,887.5%-4.92%Free Sign Up
03/2024-36.68/-36.684.61B/4.61B0%0%Free Sign Up
12/2023-2.56/-2.567.29B/7.29B0%0%Free Sign Up

All numbers in JPY

Nxera Pharma Co Ltd Earnings Call Summary for Q4/2025

  • Nxera Pharma reported Q4 2025 revenue growth to JPY 29.6 billion, yet stock fell 0.91% amid investor concerns over core operating loss of JPY 400 million and declining milestone revenue.
  • Product sales rose to JPY 17.8 billion, with Quviviq showing 224% year-on-year growth, while milestone revenue decreased to JPY 9.7 billion from JPY 11.2 billion.
  • CEO Chris Cargill outlined a strategy balancing research investment with profitability goals, as the company faces cash burn concerns with negative levered free cash flow of USD 94.46M.
  • For FY 2026, Nxera targets net product sales exceeding JPY 19.5 billion, aims for full-year profitability, plans to secure late-stage products, and intends to reduce costs by 10%.
Last Updated: 13/02/2026, 09:16
Read Full Transcript

FAQ

What Is Nxera Pharma's Earnings Per Share (TTM)?

The Nxera Pharma EPS (TTM) is -68.17.

When Is The Next Nxera Pharma (4565) Earnings Date?

Nxera Pharma will release its next earnings report on 08/05/2026.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.